Influenza vaccination in patients with asthma: effect on peak expiratory flow, asthma symptoms and use of medication

Vaccine. 1997 Jun;15(9):1008-9. doi: 10.1016/s0264-410x(96)00285-x.

Abstract

This pilot study was undertaken to examine whether killed influenza vaccine causes exacerbations in asthmatic adults. Thirty-three stable asthmatics recorded peak expiratory flow (PEF), asthma symptoms, and use of asthma medication for 2 weeks, and then received killed influenza vaccine. Thereafter they recorded PEF, asthma symptoms and use of medication for a further 2 weeks. Comparison of recordings during the 2 weeks before and after vaccination revealed that influenza vaccine was not associated with reduction in PEF (P = 0.76), increase in asthma symptoms (P = 0.17) or use of asthma medication (P = 0.58). Similar results for PEF (P = 0.49), asthma symptoms (P = 0.17), and asthma medication (P = 0.16) were obtained when the analysis was restricted to the 2 days before and after vaccination.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Anti-Asthmatic Agents / therapeutic use*
  • Asthma / drug therapy*
  • Asthma / immunology
  • Asthma / physiopathology*
  • Female
  • Humans
  • Influenza Vaccines / adverse effects*
  • Male
  • Middle Aged
  • Peak Expiratory Flow Rate / immunology
  • Pilot Projects
  • Vaccines, Inactivated / adverse effects

Substances

  • Anti-Asthmatic Agents
  • Influenza Vaccines
  • Vaccines, Inactivated